Novo Nordisk A/S (NVO)

Novo Nordisk A/S's stock is severely oversold as the market overreacts to short-term news, which has created what appears to be a rare buying opportunity. While Q2 guidance was lowered, the underlying...

Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo.

Novo Nordisk (NVO) reached $54.87 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in ...

It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard H...

Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid in...

Finding undervalued stocks isn't easy these days. The average stock price for companies in the benchmark S&P 500 index has soared to 24.8 times trailing 12-month earnings.

Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroa...

Novo Nordisk A/S's job cuts and profit outlook reset reflect a strategic pivot to margin discipline, not long-term weakness, amid evolving GLP-1 market dynamics. Despite near-term margin pressure and ...